Literature DB >> 28411587

Novel STAC3 Mutations in the First Non-Amerindian Patient with Native American Myopathy.

Michelle Grzybowski1, Anne Schänzer2, Alexander Pepler3, Corina Heller3, Bernd A Neubauer1, Andreas Hahn1.   

Abstract

Native American myopathy (NAM) is an autosomal recessive congenital myopathy, up till now exclusively described in Lumbee Indians who harbor one single homozygous mutation (c.1046G>C, pW284S) in the STAC3 gene, encoding a protein important for proper excitation-contraction coupling in muscle. Here, we report the first non-Amerindian patient of Turkish ancestry, being compound heterozygous for the mutations c.862A>T (p.K288*) and c.432+4A>T (aberrant splicing with skipping of exon 4). Symptoms in NAM include congenital muscle weakness and contractures, progressive scoliosis, early ventilatory failure, a peculiar facial gestalt with mild ptosis and downturned corners of the mouth, short stature, and marked susceptibility to malignant hyperthermia. This case shows that NAM should also be considered in non-Indian patients with congenital myopathy, and suggests that STAC3 mutations should be taken into account as a potential cause of malignant hyperthermia. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28411587     DOI: 10.1055/s-0037-1601868

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

1.  Identification of STAC3 variants in non-Native American families with overlapping features of Carey-Fineman-Ziter syndrome and Moebius syndrome.

Authors:  Aida Telegrafi; Bryn D Webb; Sarah M Robbins; Carlos E Speck-Martins; David FitzPatrick; Leah Fleming; Richard Redett; Andreas Dufke; Gunnar Houge; Jeske J T van Harssel; Alain Verloes; Angela Robles; Irini Manoli; Elizabeth C Engle; Ethylin W Jabs; David Valle; John Carey; Julie E Hoover-Fong; Nara L M Sobreira
Journal:  Am J Med Genet A       Date:  2017-08-04       Impact factor: 2.802

2.  Recessive MYF5 Mutations Cause External Ophthalmoplegia, Rib, and Vertebral Anomalies.

Authors:  Silvio Alessandro Di Gioia; Sherin Shaaban; Beyhan Tüysüz; Nursel H Elcioglu; Wai-Man Chan; Caroline D Robson; Kirsten Ecklund; Nicole M Gilette; Azmi Hamzaoglu; Gulsen Akay Tayfun; Elias I Traboulsi; Elizabeth C Engle
Journal:  Am J Hum Genet       Date:  2018-06-07       Impact factor: 11.025

Review 3.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.

Authors:  Stephen G Gonsalves; Robert T Dirksen; Katrin Sangkuhl; Rebecca Pulk; Maria Alvarellos; Teresa Vo; Keiko Hikino; Dan Roden; Teri E Klein; S Mark Poler; Sephalie Patel; Kelly E Caudle; Ronald Gordon; Barbara Brandom; Leslie G Biesecker
Journal:  Clin Pharmacol Ther       Date:  2019-01-24       Impact factor: 6.875

4.  Duplex signaling by CaM and Stac3 enhances CaV1.1 function and provides insights into congenital myopathy.

Authors:  Jacqueline Niu; Wanjun Yang; David T Yue; Takanari Inoue; Manu Ben-Johny
Journal:  J Gen Physiol       Date:  2018-06-27       Impact factor: 4.086

Review 5.  A framework for the evaluation of patients with congenital facial weakness.

Authors:  Bryn D Webb; Irini Manoli; Elizabeth C Engle; Ethylin W Jabs
Journal:  Orphanet J Rare Dis       Date:  2021-04-07       Impact factor: 4.123

6.  The First Russian Patient with Native American Myopathy.

Authors:  Aysylu Murtazina; Nina Demina; Polina Chausova; Olga Shchagina; Artem Borovikov; Elena Dadali
Journal:  Genes (Basel)       Date:  2022-02-13       Impact factor: 4.096

Review 7.  Mutations in proteins involved in E-C coupling and SOCE and congenital myopathies.

Authors:  Daniela Rossi; Maria Rosaria Catallo; Enrico Pierantozzi; Vincenzo Sorrentino
Journal:  J Gen Physiol       Date:  2022-08-18       Impact factor: 4.000

Review 8.  Skeletal muscle CaV1.1 channelopathies.

Authors:  Bernhard E Flucher
Journal:  Pflugers Arch       Date:  2020-03-28       Impact factor: 3.657

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.